<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>239-FOSAMPRENAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase or of decrease of the effects of the A to take into account buprenorphine [sic], simultaneously by inhibition and acceleration of its metabolism by the protease inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>239-FOSAMPRENAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of lower effectiveness of the amprenavir.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>239-FOSAMPRENAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Significant decrease of the concentrations of amprenavir that can lead to a loss of viralogical response</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>239-FOSAMPRENAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ampernavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and possible adjustment of the dosage of methadone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>239-FOSAMPRENAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of lower effectiveness of the amprenavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.</COMMENT>
</INTERACTION>
</INTERACTIONS>
